Q-omics provides the consensus-scored PRSS8 profile across patient tissues and cancer cell-line models. PRSS8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRSS8 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PRSS8 RNA expression shows 14,571 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where PRSS8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS8 survival associations across molecular data types. PRSS8 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS8 RNA expression–survival associations across cancer types. High PRSS8 expression shows unfavorable associations in BLCA, SKCM and LGG, but favorable associations in KIRC, UVM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRSS8 RNA expression.
This table summarizes PRSS8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PRSS8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS8 shows lower tumor expression in KIRC, COAD and LIHC and higher tumor expression in BLCA, UCEC and BRCA. The KIRC box plot shows higher PRSS8 RNA expression in normal versus tumor tissue (log2 FC = −2.214, t-test p < 0.001).
This table shows molecular features associated with PRSS8 in patient tissues and cancer cell lines. In patient samples, PRSS8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
